Mirdametinib for relapsed or refractory CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a drug called mirdametinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if mirdametinib can help shrink the cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CLL or SLL that has come back or not responded to previous treatments.
- You have already tried at least two different treatments, including a BTK inhibitor (like ibrutinib or acalabrutinib) and a BCL2 inhibitor (like venetoclax).
- Your CLL is causing symptoms that need treatment, such as an enlarged spleen, large lymph nodes, fatigue, fevers, night sweats, weight loss, or worsening blood counts.
- You have measurable signs of the disease, like a high lymphocyte count, enlarged lymph nodes, or bone marrow involvement.
- You are at least 18 years old and your overall health is fairly good (able to do daily activities with some help if needed).
- Your kidney, liver, and blood counts meet specific minimum levels, and you do not have uncontrolled infections or certain heart or eye problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
This trial tests a new combination of medications for mantle cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combination can shrink tumors and is safe for patients like you.
This study tests two targeted oral medications, zanubrutinib and sonrotoclax, for people with CLL or SLL that has come back. The goal is to see if combining them can control the disease better and with fewer side effects than current options.
This trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The goal is to see if this combination is safe and effective.
This trial tests a drug called mirdametinib for people with histiocytic disorders, which are rare diseases where certain immune cells grow out of control. It may help shrink tumors and improve symptoms when other treatments haven't worked.
This Phase 1/2 trial tests how safe and how well a combination of chemo and immunotherapy works when followed by a short course of a targeted “MEK” inhibitor as first treatment for metastatic lung adenocarcinoma with PD-L1 below 50%. It may help some people control cancer better, while also providing more information about side effects and the best way to use these medicines together.
Hear when a new Recurrent Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.